Evidence map›Paper›PMID 33283480›Full record

ArticleMacromolecular bioscience2021

Hybrid Curdlan Poly(γ -Glutamic Acid) Nanoassembly for Immune Modulation in Macrophage.

Jeongyun Heo, Thomas A Sobiech, Hilliard L Kutscher, Lee Chaves, Dinesh K Sukumaran, Shanta Karki, Admire Dube, Paras N Prasad, Jessica L Reynolds

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Macromolecular bioscience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Synthesis of immunomodulatory biomimetic lipid polymer hybrid nanoparticles and application of zebrafish larvae in immunomodulation screening.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2025
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jeongyun HeoInstitute for Laser, Photonics and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA.
Thomas A SobiechDepartment of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA.
Hilliard L KutscherInstitute for Laser, Photonics and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA.
Lee ChavesDivision of Nephrology, Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY, 14203, USA.
Dinesh K SukumaranDepartment of Chemistry, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA.
Shanta KarkiDivision of Allergy, Immunology, and Rheumatology, Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY, 14203, USA.
Admire DubeSchool of Pharmacy, University of the Western Cape, Bellville, Cape Town, 7535, South Africa.
Paras N PrasadInstitute for Laser, Photonics and Biophotonics, University at Buffalo, The State University of New York, Buffalo, NY, 14260, USA.
Jessica L ReynoldsDivision of Allergy, Immunology, and Rheumatology, Department of Medicine, Clinical Translational Research Center, The State University of New York at Buffalo, Buffalo, NY, 14203, USA.
University at Buffalo, State University of New York · USUniversity of the Western Cape · ZA

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Institutional Career DevelopmentKL2TR001413 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI DUBOCOVICH, MARGARITA L · 2015 to 2024
$4.2M
Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeuticnanoparticles for TBR01AI129649 · NIAID · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI REYNOLDS, JESSICA L · 2018 to 2022
$2.2M
Nanoparticle-based host-directed therapies for eradication of Mycobacterium tuberculosisR01AI152109 · NIAID · STELLENBOSCH UNIVERSITY · PI DUBE, ADMIRE, REINEKE, JOSHUA JAMES · 2020 to 2024
$1.6M
Development of Nanomedicines for Tuberculosis TreatmentK43TW010371 · FIC · UNIVERSITY OF THE WESTERN CAPE · PI DUBE, ADMIRE · 2017 to 2021
$370k
FIC NIH HHS K43 TW010371NCATS NIH HHS KL2 TR001413NCATS NIH HHS UL1 TR001412NIAID NIH HHS R01 AI129649NIAID NIH HHS R01 AI152109
6 · The paper itself

Abstract

A nanoformulation composed of curdlan, a linear polysaccharide of 1,3-β-linked d-glucose units, hydrogen bonded to poly(γ -glutamic acid) (PGA), was developed to stimulate macrophage. Curdlan/PGA nanoparticles (C-NP) are formulated by physically blending curdlan (0.2 mg mL

Indexed as

beta-GlucansChemokinesCytokinesFluorescence Resonance Energy TransferGene Expression RegulationHumansHydrogenImmunomodulationMacrophagesNanoparticlesPolyglutamic Acidbeta-GlucansChemokinescurdlanCytokinesHydrogenPolyglutamic Acidcurdlancytokineshydrogen bondingimmunotherapypoly(γ-glutamic acid)

Identifiers

PMID33283480
PMCPMC7839312
OpenAlexW3112373408

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.